Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SGRY
stocks logo

SGRY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
866.54M
+0.25%
0.298
-32.37%
824.24M
+6.22%
-0.008
-119.15%
888.01M
+7.48%
0.146
-13.98%
Estimates Revision
The market is revising Downward the revenue expectations for Surgery Partners, Inc. (SGRY) for FY2025, with the revenue forecasts being adjusted by -1.58% over the past three months. During the same period, the stock price has changed by -22.79%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.58%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-25.37%
In Past 3 Month
Stock Price
Go Down
down Image
-22.79%
In Past 3 Month
Wall Street analysts forecast SGRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGRY is 26.60 USD with a low forecast of 18.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast SGRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGRY is 26.60 USD with a low forecast of 18.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 17.380
sliders
Low
18.00
Averages
26.60
High
36.00
Current: 17.380
sliders
Low
18.00
Averages
26.60
High
36.00
JPMorgan
Neutral
downgrade
$27 -> $20
2025-11-24
Reason
JPMorgan
Price Target
$27 -> $20
2025-11-24
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Surgery Partners to $20 from $27 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q3 report.
Barclays
Equal Weight
downgrade
$24 -> $18
2025-11-21
Reason
Barclays
Price Target
$24 -> $18
2025-11-21
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Surgery Partners to $18 from $24 and keeps an Equal Weight rating on the shares. The firm says employer-sponsored insurance coverage looks under pressure but will be "potentially masked" by positive Affordable Care Act trends benefiting hospitals.
Mizuho
Outperform
to
NULL
downgrade
$28 -> $22
2025-11-17
Reason
Mizuho
Price Target
$28 -> $22
2025-11-17
downgrade
Outperform
to
NULL
Reason
Mizuho lowered the firm's price target on Surgery Partners to $22 from $28 and keeps an Outperform rating on the shares. The firm reduced its estimates for Surgery Partners to account for the lower-than-expected performance, lower earnings visibility due to payer mix pressure, and to remove M&A from its forecasts. Though the payer mix volume pressures reduce earnings visibility, the firm believes its estimates reflect that risk.
UBS
Buy
downgrade
$34 -> $29
2025-11-13
Reason
UBS
Price Target
$34 -> $29
2025-11-13
downgrade
Buy
Reason
UBS lowered the firm's price target on Surgery Partners to $29 from $34 and keeps a Buy rating on the shares.
Benchmark
Buy
maintain
$35 -> $30
2025-11-11
Reason
Benchmark
Price Target
$35 -> $30
2025-11-11
maintain
Buy
Reason
Benchmark lowered the firm's price target on Surgery Partners to $30 from $35 and keeps a Buy rating on the shares after the company reported an in-line Q3, but also guided Q4 below consensus, resulting in FY25 AEBITDA guidance being reduced 4% at the midpoint. The firm thinks timing issues will begin to resolve by the time Surgery reports Q4 results, which it thinks should enable management to guide 2026 for double-digit AEBITDA growth and to point to incremental progress on portfolio optimization and deleveraging, the analyst tells investors.
RBC Capital
Outperform
downgrade
$35 -> $31
2025-11-11
Reason
RBC Capital
Price Target
$35 -> $31
2025-11-11
downgrade
Outperform
Reason
RBC Capital lowered the firm's price target on Surgery Partners to $31 from $35 but keeps an Outperform rating on the shares after its Q3 earnings miss. Some stock price weakness was to be expected, but the magnitude of the move is overdone, especially given that the M&A backdrop remains favorable and the long-term same-store algorithm remains intact, the analyst tells investors in a research note. While the management pointed to slowing volume and payer mix trends, these developments bring 2025 adjusted EBITDA guidance down to the midpoint of their long-term algorithm, the firm added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Surgery Partners Inc (SGRY.O) is 28.04, compared to its 5-year average forward P/E of -329.60. For a more detailed relative valuation and DCF analysis to assess Surgery Partners Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-329.60
Current PE
28.04
Overvalued PE
1283.47
Undervalued PE
-1942.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
18.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
21.63
Undervalued EV/EBITDA
14.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.24
Current PS
0.00
Overvalued PS
1.63
Undervalued PS
0.85
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 682.35% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SGRY News & Events

Events Timeline

(ET)
2025-11-10
14:25:23
Surgery Partners announces Q3 adjusted EPS of 13 cents, below consensus estimate of 18 cents.
select
2025-11-10
14:23:25
Surgery Partners lowers FY25 revenue forecast to $3.275B-$3.3B, down from $3.3B-$3.45B
select
2025-11-10
12:00:03
Surgery Partners Experiences a 24.3% Decline
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-20PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Surgery Partners, Inc. and its executives, urging affected investors to reach out for assistance.

  • Financial Results and Guidance Revision: On November 10, 2025, Surgery Partners reported a decrease in its full-year revenue and adjusted EBITDA guidance, attributing the changes to delays in capital deployment and other operational challenges.

  • Stock Price Impact: Following the announcement of the revised financial guidance, Surgery Partners' stock price dropped significantly by 25.42%, closing at $16.04 per share.

  • Pomerantz LLP Background: Pomerantz LLP is a well-established law firm specializing in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct.

[object Object]
Preview
4.0
11-18Benzinga
Mizuho Keeps Outperform Rating for Surgery Partners, Adjusts Price Target to $22

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve trading outcomes.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

[object Object]
Preview
6.0
11-14NASDAQ.COM
UBS Continues to Recommend Buying Surgery Partners (SGRY)

  • UBS Coverage and Price Target: UBS has maintained a Buy recommendation for Surgery Partners (NasdaqGS:SGRY) as of November 13, 2025, with an average one-year price target of $31.82/share, indicating a potential upside of 107.73% from its current price of $15.32/share.

  • Projected Revenue and EPS: Surgery Partners is projected to have an annual revenue of $3,318 million, reflecting a 0.91% increase, with a non-GAAP EPS forecast of 1.90.

  • Fund Sentiment and Ownership Changes: There are 458 funds reporting positions in Surgery Partners, with a slight decrease in ownership by 2.55% over the last quarter, while total shares owned by institutions increased by 2.59% to 170,763K shares.

  • Shareholder Activity: Bain Capital Investors remains the largest shareholder with 38.88% ownership, while other firms like Janus Henderson Group and Pentwater Capital Management have adjusted their holdings, with Pentwater increasing its stake by 60.83%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Surgery Partners Inc (SGRY) stock price today?

The current price of SGRY is 17.38 USD — it has increased 2 % in the last trading day.

arrow icon

What is Surgery Partners Inc (SGRY)'s business?

Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility Services segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of 162 surgical facilities comprised of 143 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 250 locations in 30 states, including short-stay surgical hospitals.

arrow icon

What is the price predicton of SGRY Stock?

Wall Street analysts forecast SGRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGRY is 26.60 USD with a low forecast of 18.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Surgery Partners Inc (SGRY)'s revenue for the last quarter?

Surgery Partners Inc revenue for the last quarter amounts to 821.50M USD, increased 6.63 % YoY.

arrow icon

What is Surgery Partners Inc (SGRY)'s earnings per share (EPS) for the last quarter?

Surgery Partners Inc. EPS for the last quarter amounts to -0.18 USD, decreased -28.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Surgery Partners Inc (SGRY)'s fundamentals?

The market is revising Downward the revenue expectations for Surgery Partners, Inc. (SGRY) for FY2025, with the revenue forecasts being adjusted by -1.58% over the past three months. During the same period, the stock price has changed by -22.79%.
arrow icon

How many employees does Surgery Partners Inc (SGRY). have?

Surgery Partners Inc (SGRY) has 15000 emplpoyees as of December 05 2025.

arrow icon

What is Surgery Partners Inc (SGRY) market cap?

Today SGRY has the market capitalization of 2.25B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free